Lakefront Biotherapeutics NV

Over the past 90 days, Lakefront Biotherapeutics NV (GLPGF) shows no detected cyber incidents, no red-flag 8-K filings, and no officer departures or restatement events in our ingestion pipeline. The absence of acute disclosure events in this window is notable, though low signal in 90 days does not indicate low structural risk—the company operates in a capital-intensive biotech sector where dilution and financing pressures often build gradually. The full $49 Report extends the analysis across 12 months of SEC filings, calculates dilution risk scores from equity issuance patterns, maps the complete financing history, and surfaces AI-detected anomalies in MD&A language and cash burn trends. The full $49 Report adds quantified dilution trajectory, 12-month red-flag context, and early-warning signals that raw filings alone can miss.